Latigo Biotherapeutics, Inc. (LTGO)

NASDAQ: LTGO · Real-Time Price · USD

12.60

-0.41 (-3.15%)

At close: Nov 6, 2026, 4:00 PM EST

12.57

-0.03 (-0.22%)

After-hours: Nov 6, 2026, 6:57 PM EST

Latigo Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	18.4	10.86	6.67
Research & Development	92.18	99.53	56.78
Operating Expenses	110.59	110.39	63.45
Operating Income	-110.59	-110.39	-63.45
Interest & Investment Income	3.69	2.94	2.26
Other Non Operating Income (Expenses)	5.13	-1.72	0
Pretax Income	-107.29	-109.17	-61.18
Net Income	-107.29	-109.17	-61.18
Net Income to Common	-107.29	-109.17	-61.18
Net Income Growth	-	-	-
Shares Outstanding (Basic)	10	1	1
Shares Outstanding (Diluted)	10	1	1
Shares Change	1126.55%	24.39%	-
EPS (Basic)	-10.41	-129.23	-90.10
EPS (Diluted)	-10.42	-129.23	-90.10
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-	-97.69	-51.03
Free Cash Flow Per Share	-	-115.65	-75.14
EBITDA	-110.38	-110.14	-63.21
D&A For EBITDA	0.21	0.25	0.24
EBIT	-110.59	-110.39	-63.45

SEC Filings: 10-K · 10-Q